| Detailed information |
|---|
| CancerLivER ID | 2156 |
| Biomarker | CAF-1, HSP60 |
| Biomarker Name/Symbol (given in Publication) | CAF-1 and HSP60 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential new biomarkers that are able to predict HCC development at earlier stages and validated on independent dataset |
| Experimental Condition | Normal vs HCC with Hepatitis C and without Hepatitis C |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.05 |
| Source | Urine |
| PMID | 23074380 |
| Type of Biomarker | Diagnostic |
| Pathway | P13K-Akt-PKB |
| Cohort | Training Dataset:106 Hepatitis C infected patients patients, 32 of whom had already developed Hepatocellular Carcinoma; Validation dataset: 74 patients who were diagnosed as Hepatocellular Carcinoma -free at the time of initial sample collection,12 healthy control individuals |
| Sensitivity | 92% |
| Specificity | 61% |
| Accuracy | 77% |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2012 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |